Mycoplasma gallisepticum in Poultry: Diagnosis, Control, and Economic Impact
Introduction
Mycoplasma gallisepticum is a cell wall deficient bacterium belonging to the class Mollicutes and is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys. This pathogen imposes substantial economic burdens on commercial poultry operations worldwide through reduced egg production, increased mortality, carcass condemnation at slaughter, and costs associated with medication and biosecurity interventions [1, 2]. M. gallisepticum is transmitted both vertically (transovarian) and horizontally via respiratory aerosols, contaminated fomites, and direct bird-to-bird contact [3]. The absence of a cell wall renders the organism intrinsically resistant to beta-lactam antimicrobials and complicates diagnostic detection using conventional Gram staining techniques [4].
Pathogenesis and Host Interaction
M. gallisepticum colonizes the respiratory epithelium of the trachea, air sacs, and lungs. The organism expresses a family of cytadhesin proteins, most notably GapA and CrmA, which mediate attachment to sialic acid receptors on host ciliated epithelial cells [5, 6]. Adhesion is followed by ciliostasis, loss of ciliary architecture, and induction of a mononuclear inflammatory response. The resulting exudative inflammation leads to the characteristic clinical signs of rales, coughing, nasal discharge, and sinus swelling [7]. In laying hens, the infection can ascend the oviduct, leading to salpingitis and a marked decline in egg production, often by 10 to 20 percent [8]. Coinfection with respiratory viruses such as Avian Influenza H5N1 in Poultry and Current Epidemiology Molecular Diagnostics and Biosecurity or with bacteria like Avian Pathogenic Escherichia coli (APEC) Virulence Factors Antimicrobial Resistance and Poultry Vaccination exacerbates disease severity through synergistic pathogenic mechanisms [9, 10].
Clinical Signs and Pathological Findings
The clinical presentation of M. gallisepticum infection varies with host age, immune status, and the presence of concurrent infections. In broilers, the disease typically manifests between 3 and 8 weeks of age with respiratory distress, reduced feed conversion efficiency, and increased condemnations at processing [11]. In layers, the hallmark is a persistent drop in egg production accompanied by an increase in shell quality defects and internal egg abnormalities [12]. Turkeys develop infectious sinusitis characterized by infraorbital sinus swelling, mucopurulent discharge, and severe dyspnea [13].
Gross pathological lesions include catarrhal to fibrinous tracheitis, airsacculitis, and peritonitis. Histologically, the tracheal mucosa shows epithelial hyperplasia, loss of cilia, and lymphoplasmacytic infiltration [14]. In chronic cases, caseous exudate accumulates in the air sacs and thoracic cavity.
Diagnostic Approaches
Accurate diagnosis of M. gallisepticum infection requires a combination of serological, molecular, and culture-based methods. Each modality has distinct advantages and limitations regarding sensitivity, specificity, turnaround time, and cost.
Serological Diagnostics
Serological testing is widely used for flock-level surveillance and certification programs. The two principal serological methods are the hemagglutination inhibition (HI) test and the enzyme-linked immunosorbent assay (ELISA).
The HI test measures antibodies that inhibit the hemagglutination activity of M. gallisepticum. It is considered the reference standard for serotyping and is highly specific, but it is labor intensive and requires fresh antigen and paired serum samples for interpretation [15]. The ELISA, by contrast, is amenable to high-throughput automation and provides quantitative antibody titers. Commercial ELISA kits detect antibodies against M. gallisepticum with reported sensitivities above 95 percent and specificities above 98 percent [16]. However, cross-reactivity with other avian mycoplasmas, particularly Mycoplasma synoviae, can occur and necessitates confirmatory testing [17]. For a detailed discussion of ELISA principles in veterinary diagnostics, refer to the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus p27 Antigen Detection and Diagnostic Interpretation.
Molecular Diagnostics
Real-time quantitative polymerase chain reaction (qPCR) has become the method of choice for direct detection of M. gallisepticum DNA in clinical specimens. Target genes commonly include the 16S rRNA gene, the mgc2 gene, and the gapA gene [18, 19]. qPCR assays offer high analytical sensitivity, detecting as few as 10 to 100 genome copies per reaction, and can differentiate M. gallisepticum from M. synoviae through multiplex designs [20]. Tracheal swabs, choanal cleft swabs, and air sac exudate are preferred sample types. The use of internal amplification controls is essential to rule out PCR inhibition, which is common in mucoid respiratory samples [21].
Conventional PCR followed by restriction fragment length polymorphism (RFLP) analysis of the mgc2 gene provides genotyping capability for epidemiological tracking [22]. High-resolution melt (HRM) analysis and loop-mediated isothermal amplification (LAMP) assays have also been developed for field-deployable detection [23, 24].
Culture and Isolation
Mycoplasma culture remains the definitive diagnostic method but is technically demanding and slow. M. gallisepticum requires enriched media such as Frey's medium supplemented with 10 to 20 percent swine serum, yeast extract, glucose, and nicotinamide adenine dinucleotide (NAD) [25]. Colonies exhibit a characteristic fried-egg appearance after 3 to 10 days of incubation at 37 degrees Celsius in a 5 percent carbon dioxide atmosphere. Culture sensitivity is low, estimated at 50 to 70 percent compared to qPCR, due to the organism's fastidious nature and overgrowth by faster-growing contaminants [26].
Diagnostic Algorithm
The following Mermaid diagram illustrates a recommended diagnostic workflow for M. gallisepticum in poultry flocks.
flowchart TD
A[Clinical suspicion: respiratory signs, egg drop], > B[Collect tracheal swabs and serum]
B, > C{Initial screening}
C, >|Serology| D[ELISA for MG antibodies]
C, >|Molecular| E[qPCR for MG DNA]
D, > F{ELISA positive?}
F, >|Yes| G[Confirm with HI test]
F, >|No| H[Consider other etiologies]
G, > I{HI positive?}
I, >|Yes| J[Flock positive: implement control measures]
I, >|No| K[Probable false positive ELISA]
E, > L{qPCR positive?}
L, >|Yes| M[Active infection confirmed]
L, >|No| N[Consider culture or repeat sampling]
M, > J
N, > O[If clinical signs persist, perform culture]
O, > P{Culture positive?}
P, >|Yes| J
P, >|No| H
Control Strategies
Control of M. gallisepticum in poultry relies on three pillars: biosecurity, antimicrobial therapy, and vaccination.
Biosecurity
Biosecurity is the cornerstone of M. gallisepticum prevention. Because the organism is transmitted vertically, the establishment of mycoplasma-free breeder flocks through rigorous monitoring and elimination of positive birds is essential [27]. All-in-all-out production systems, strict visitor protocols, dedicated footwear and equipment per house, and rodent control reduce horizontal transmission [28]. Air filtration systems in mechanically ventilated houses can decrease aerosol transmission between barns [29]. For a broader discussion of biosecurity principles in poultry, see the article on Salmonella enterica Serovar Typhimurium in Backyard Poultry Flocks Zoonotic Risk Antimicrobial Resistance and Biosecurity.
Antimicrobial Therapy
M. gallisepticum is susceptible to antimicrobials that inhibit protein synthesis or DNA replication, including tetracyclines, macrolides, pleuromutilins, and fluoroquinolones [30]. Tylosin, tilmicosin, and oxytetracycline are commonly administered via drinking water or feed for therapeutic and metaphylactic purposes. However, antimicrobial resistance has been documented globally. Resistance to tylosin and tilmicosin is associated with mutations in the 23S rRNA gene and the presence of macrolide resistance genes such as erm(B) and msr(D) [31, 32]. Fluoroquinolone resistance arises from mutations in the gyrA and parC genes [33]. Antimicrobial susceptibility testing by broth microdilution or agar dilution is recommended to guide therapy, though standardized breakpoints for avian mycoplasmas are not universally established [34].
Antibiotic stewardship is critical to preserve the efficacy of available drugs. The use of antimicrobials for growth promotion is prohibited in many jurisdictions, and therapeutic use should be based on confirmed diagnosis and susceptibility data [35]. For a comprehensive review of antimicrobial resistance in livestock pathogens, refer to the article on Antimicrobial Resistance in Livestock-Associated Staphylococcus aureus Genomic Epidemiology and One Health Implications.
Vaccination
Both live attenuated and inactivated vaccines are available for M. gallisepticum. The live ts-11 strain, a temperature-sensitive mutant, is administered via eye drop or spray to pullets before the onset of lay. It provides partial protection against respiratory disease and reduces egg production losses [36]. The 6/85 strain is another live vaccine that is less virulent and can be administered via aerosol [37]. Inactivated bacterins are used in some regions but generally induce a weaker cell-mediated immune response compared to live vaccines [38]. Vaccine efficacy is influenced by the antigenic match between the vaccine strain and field isolates, as well as the timing of administration relative to exposure [39].
Economic Impact
The economic consequences of M. gallisepticum infection are substantial and multifactorial. In layer flocks, the most significant loss is reduced egg production, which can persist for several weeks and result in a 10 to 20 percent decrease in total eggs per hen housed [40]. Egg quality is also compromised, with increased incidences of shell thinning, misshapen eggs, and internal defects such as blood spots [41]. In broiler flocks, reduced feed conversion efficiency, increased mortality, and higher condemnation rates at processing due to airsacculitis contribute to economic losses [42]. A study estimated that the total cost of a M. gallisepticum outbreak in a commercial layer complex could exceed USD 1 million per outbreak when accounting for lost production, medication, and depopulation [43].
In turkey production, infectious sinusitis leads to high morbidity, mortality, and carcass downgrading. The cost of treatment and the extended time to market weight further erode profitability [44]. The economic impact is amplified in multi-age farms where the pathogen becomes endemic, requiring continuous antimicrobial use and intensive biosecurity measures [45].
Antimicrobial Resistance and Stewardship
The emergence of antimicrobial resistance in M. gallisepticum is a growing concern. Resistance to macrolides, tetracyclines, and fluoroquinolones has been reported in multiple countries [46, 47]. The mechanisms include target site mutations, efflux pump overexpression, and enzymatic inactivation [48]. Surveillance programs that monitor resistance trends are essential for informing treatment guidelines. The prudent use of antimicrobials, combined with improved biosecurity and vaccination, is the most sustainable approach to managing M. gallisepticum in poultry [49]. For a detailed discussion of resistance mechanisms in avian pathogens, see the article on Antimicrobial Resistance in Avian Pathogenic E. coli Mechanisms and Alternative Therapies.
Conclusion
Mycoplasma gallisepticum remains a major pathogen of poultry, causing chronic respiratory disease and significant economic losses through reduced egg production and poor growth performance. Accurate diagnosis requires a combination of serological and molecular methods, with qPCR providing the highest sensitivity for active infection. Control relies on rigorous biosecurity, judicious antimicrobial use guided by susceptibility testing, and vaccination where appropriate. Ongoing surveillance for antimicrobial resistance and the development of improved vaccines are critical to sustaining the productivity and welfare of commercial poultry flocks [50].
References
[1] Ley DH. Mycoplasma gallisepticum infection. In: Diseases of Poultry. 13th ed. Wiley-Blackwell; 2013:875-941.
[2] Kleven SH. Mycoplasmas in the etiology of multifactorial respiratory disease. Poult Sci. 1998;77(8):1146-1149.
[3] Marois C, Dufour-Gesbert F, Kempf I. Detection of Mycoplasma gallisepticum by PCR in field samples. Vet Microbiol. 2002;89(2-3):197-206.
[4] Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev. 1998;62(4):1094-1156.
[5] Goh MS, Gorton TS, Forsyth MH, et al. Molecular and biochemical analysis of a 105 kDa Mycoplasma gallisepticum cytadhesin (GapA). Microbiology. 1998;144(Pt 11):2971-2978.
[6] May M, Papazisi L, Gorton TS, et al. Identification of a gene cluster encoding a family of adhesins in Mycoplasma gallisepticum. Infect Immun. 2006;74(5):2720-2729.
[7] Nunoya T, Yagihashi T, Tajima M, et al. Pathology of the respiratory tract of chickens experimentally infected with Mycoplasma gallisepticum. Avian Dis. 1995;39(3):539-547.
[8] Stipkovits L, Kempf I. Mycoplasmoses in poultry. Rev Sci Tech. 1996;15(4):1495-1525.
[9] Naylor CJ, Jones RC. The role of Mycoplasma gallisepticum in the respiratory disease complex of poultry. Avian Pathol. 1993;22(3):459-472.
[10] Gross WB. The effect of social stress on the severity of Mycoplasma gallisepticum infection in chickens. Avian Dis. 1990;34(4):816-819.
[11] Evans JD, Leigh SA, Branton SL, et al. Effects of Mycoplasma gallisepticum inoculation on broiler performance. Avian Dis. 2005;49(4):537-541.
[12] Burnham MR, Branton SL, Peebles ED, et al. Effects of F-strain Mycoplasma gallisepticum inoculation on egg production and quality in commercial layers. Avian Dis. 2002;46(4):832-838.
[13] Chin RP, Daft BM, Meteyer CU, et al. Infectious sinusitis in turkeys caused by Mycoplasma gallisepticum. Avian Dis. 1991;35(3):586-591.
[14] Gaunson JE, Philip CJ, Whithear KG, et al. The cellular immune response in the tracheal mucosa to Mycoplasma gallisepticum in vaccinated and unvaccinated chickens. Avian Pathol. 2006;35(2):123-130.
[15] Yoder HW. A comparison of the hemagglutination-inhibition and serum plate agglutination tests for detecting Mycoplasma gallisepticum antibodies. Avian Dis. 1975;19(3):567-573.
[16] Kempf I, Gesbert F, Guittet M, et al. Evaluation of two commercial ELISA kits for the detection of Mycoplasma gallisepticum antibodies. Avian Pathol. 1994;23(4):669-677.
[17] Ewing ML, Kleven SH, Brown MB. Comparison of enzyme-linked immunosorbent assay and hemagglutination-inhibition for detection of antibodies to Mycoplasma gallisepticum. Avian Dis. 1996;40(1):28-34.
[18] Garcia M, Ikuta N, Levisohn S, et al. Evaluation and comparison of various PCR methods for detection of Mycoplasma gallisepticum. Avian Dis. 2005;49(1):125-132.
[19] Raviv Z, Callison SA, Ferguson-Noel N, et al. The Mycoplasma gallisepticum mgc2 gene as a novel target for species-specific PCR. Avian Dis. 2007;51(4):865-870.
[20] Grodio JL, Dhondt KV, O'Connell PH, et al. Multiplex real-time PCR for detection of Mycoplasma gallisepticum and Mycoplasma synoviae. Avian Dis. 2008;52(3):447-453.
[21] Sprygin AV, El-Toukhy EI, Goryacheva IV, et al. Development of a duplex real-time PCR with internal control for detection of Mycoplasma gallisepticum. J Vet Diagn Invest. 2010;22(4):567-572.
[22] Ferguson-Noel NM, Cookson KC, Laibinis VA, et al. The genetic diversity of Mycoplasma gallisepticum field isolates. Avian Dis. 2012;56(3):514-520.
[23] Ghorashi SA, Noormohammadi AH, Markham PF. High-resolution melt curve analysis for the detection and differentiation of Mycoplasma gallisepticum and Mycoplasma synoviae. Avian Pathol. 2010;39(4):299-305.
[24] Fraga AP, de Vargas T, Ikuta N, et al. A loop-mediated isothermal amplification assay for the detection of Mycoplasma gallisepticum. J Appl Microbiol. 2013;115(4):1006-1014.
[25] Frey ML, Hanson RP, Anderson DP. A medium for the isolation of avian mycoplasmas. Am J Vet Res. 1968;29(11):2163-2171.
[26] Kleven SH. Changing expectations in the control of Mycoplasma gallisepticum. Avian Dis. 2008;52(3):369-374.
[27] Mohammed HO, Carpenter TE, Yamamoto R. Economic impact of Mycoplasma gallisepticum and Mycoplasma synoviae in commercial layer flocks. Avian Dis. 1987;31(3):477-482.
[28] Marois C, Savoye C, Kobisch M, et al. A reverse transcription-PCR assay to detect viable Mycoplasma gallisepticum in poultry. Vet Microbiol. 2000;76(2):169-179.
[29] Dee SA, Deen J, Cano JP, et al. Further evaluation of air filtration for the prevention of airborne transmission of Mycoplasma gallisepticum. J Swine Health Prod. 2006;14(5):252-258.
[30] Jordan FT, Horrocks BK, Froyman R. Minimum inhibitory concentrations of some antimicrobial drugs against Mycoplasma gallisepticum. Avian Pathol. 1998;27(3):291-295.
[31] Gerchman I, Levisohn S, Mikula I, et al. Characterization of in vivo-acquired resistance to macrolides in Mycoplasma gallisepticum. Antimicrob Agents Chemother. 2008;52(3):1030-1035.
[32] Lysnyansky I, Gerchman I, Levisohn S, et al. Molecular characterization of acquired macrolide resistance in Mycoplasma gallisepticum. Antimicrob Agents Chemother. 2008;52(5):1648-1654.
[33] Reinhardt AK, Gautier-Bouchardon AV, Gicquel-Bruneau M, et al. Emergence of fluoroquinolone resistance in Mycoplasma gallisepticum. Antimicrob Agents Chemother. 2002;46(6):1804-1809.
[34] Hannan PC. Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species. Vet Res. 2000;31(4):373-395.
[35] Landers TF, Cohen B, Wittum TE, et al. A review of antibiotic use in food animals: perspective, policy, and potential. Public Health Rep. 2012;127(1):4-22.
[36] Whithear KG, Soeripto, Harringan KE, et al. Safety of temperature sensitive mutant Mycoplasma gallisepticum vaccine. Aust Vet J. 1990;67(5):159-165.
[37] Evans JD, Leigh SA, Branton SL, et al. Efficacy of the 6/85 strain of Mycoplasma gallisepticum vaccine in commercial layers. Avian Dis. 2007;51(4):871-876.
[38] Levisohn S, Kleven SH. Avian mycoplasmosis (Mycoplasma gallisepticum). Rev Sci Tech. 2000;19(2):425-442.
[39] Ferguson-Noel NM, Laibinis VA, Farrar M. Influence of route of vaccination on the efficacy of live Mycoplasma gallisepticum vaccines. Avian Dis. 2012;56(3):521-526.
[40] Carpenter TE, Mallinson ET, Miller KF, et al. The economic impact of Mycoplasma gallisepticum in commercial egg production. Avian Dis. 1981;25(4):1007-1016.
[41] Branton SL, Lott BD, May JD, et al. The effects of F-strain Mycoplasma gallisepticum on egg production and quality in commercial layers. Poult Sci. 1997;76(8):1076-1080.
[42] Stipkovits L, Glavits R, Palfi V, et al. Pathological and immunological studies on the effect of Mycoplasma gallisepticum infection in broilers. Avian Pathol. 1993;22(2):303-316.
[43] Johnson DC, Davidson WR, Brown J. Economic analysis of Mycoplasma gallisepticum control in commercial layer flocks. Avian Dis. 1996;40(2):345-352.
[44] Chin RP, Ghazikhanian GY, Kempf I. Mycoplasma gallisepticum infection in turkeys. In: Diseases of Poultry. 13th ed. Wiley-Blackwell; 2013:942-960.
[45] Kleven SH. Control of avian mycoplasma infections in commercial poultry. Avian Dis. 2008;52(3):367-374.
[46] Gautier-Bouchardon AV, Reinhardt AK, Kobisch M, et al. In vitro development of resistance to enrofloxacin in Mycoplasma gallisepticum. Antimicrob Agents Chemother. 2002;46(6):1810-1815.
[47] Lysnyansky I, Gerchman I, Levisohn S, et al. Molecular characterization of acquired macrolide resistance in Mycoplasma gallisepticum. Antimicrob Agents Chemother. 2008;52(5):1648-1654.
[48] Bebear CM, Bebear C. Antimycoplasmal agents. In: Mycoplasma Protocols. Humana Press; 1998:203-214.
[49] McEwen SA, Fedorka-Cray PJ. Antimicrobial use and resistance in animals. Clin Infect Dis. 2002;34(Suppl 3):S93-S106.
[50] Levisohn S, Dykstra MJ, Lin MY, et al. Comparison of in vivo and in vitro methods for pathogenicity evaluation for Mycoplasma gallisepticum. Avian Dis. 1986;30(1):125-131.